A multidisciplinary BCC for ovarian cancer early detection: translating discoveries to clinical use with a by-design approach

用于卵巢癌早期检测的多学科 BCC：通过设计方法将发现转化为临床应用

• 批准号: 10673186
• 负责人: IE-MING SHIH
• 金额: $ 92.31万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10673186
• 关键词: Abate; Bioinformatics; Biological; Biological Assay; Biological Markers; Biology; Biomedical Engineering; Biometry; Blood specimen; Cancer Biology; Cancer Patient; Carcinoma in Situ; Chromosomal Instability; Clinical; Clinical Chemistry; Communities; Data; Data Science; Developed Countries; Development; Disease; Early Detection Research Network; Early Diagnosis; Ensure; Epithelial ovarian cancer; Epithelium; Frequencies; Funding; Future; General Population; Generations; Genes; Genomics; Goals; High Risk Woman; Histologic; Incidence; Knowledge; Level of Evidence; Low Prevalence; Malignant Neoplasms; Malignant neoplasm of ovary; Mammalian Oviducts; Mass Spectrum Analysis; Mission; Molecular; Mutation; Operative Surgical Procedures; Ovarian; Ovarian Serous Adenocarcinoma; Ovary; Pap smear; Pathogenesis; Pathology; Pathway interactions; Patients; Performance; Peritoneal; Population; Process; Recurrence; Research; Research Personnel; Resources; Risk; Sample Size; Sampling; Screening for Ovarian Cancer; Serous; Specificity; Specimen; Specimen Handling; TP53 gene; Technology; Testing; Therapeutic; Tissues; Translating; Woman; Work; assay development; biomarker development; biomarker discovery; biomarker evaluation; biomarker identification; biomarker validation; brca gene; candidate marker; candidate validation; design; disease diagnosis; early detection biomarkers; experience; genome-wide; high risk; homologous recombination; improved; in-vitro diagnostics; indexing; innovation; member; multidisciplinary; novel; process optimization; programs; sample collection; screening; sound; study population; success; tool

Project Summary (Overall) High-grade serous ovarian carcinoma (HGSOC) is the most common histological subtype of epithelial ovarian cancer. The overarching goal of the proposed Biomarker Characterization Center (BCC) is to apply a by- design approach based on biology of HGSOC pathogenesis and unmet clinical needs to identify, verify and prioritize, and validate biomarkers, and to develop them into an in vitro diagnostic multivariate index assay (IVDMIA) with the intended use to capture HGSOC in high-risk women at the early stages including i) precursors, ii) confinement to the ovary/fallopian tube or iii) low-volume diseases in high-risk women (BRCA1/2 carriers). The biomarkers that we propose to discover and validate in this proposal are intended for early detection but not necessarily for screening in general population. The BCC’s capability in advanced data generation technologies, multiplexed target assay development, and bioinformatics/data science will serve as resources for the EDRN. Based on the success of our current EDRN projects, this BCC will continue our on- going biomarker development studies including the validation of candidate biomarkers that we have identified through the current BDL. We propose the following specific aims: 1. To optimize and use novel specimen collection and processing technologies, and an iterative and cumulative process that takes advantage of our newly gained knowledge of the biology in ovarian cancer pathogenesis. BDL 2. To optimize and apply innovative bioinformatics, data sciences, and AI/ML tools that incorporate existing knowledge and data to improve discovery of low frequency biomarkers that with their functionally shared pathways/networks could collectively deliver an improved sensitivity while retaining a high specificity. BDL 3. To further develop and optimize the process for efficient multiplex targeted assay development with respect to analytical performance, throughput, and specimen volume requirement for a broad spectrum of candidate biomarkers using a “fit for purpose” approach. BRL 4. To optimize and apply a by-design approach to translating discoveries into clinical tests. Its application had been critical in the development of two FDA cleared tests by JHU team members for the preoperative assessment of ovarian malignancy risk. BDL/BRL 5. To provide expertise and analytical and data science capabilities to the entire EDRN community. The multi-disciplinary team that we have assembled (molecular cancer biology, pathology, clinical chemistry, mass spectrometry, biostatistics, data science, bioengineering), the unique, novel yet biologically and statistically sound approaches, and our long-standing experience in biomarker research and translating discoveries to FDA cleared clinical tests all together ensure the success of this proposed BCC.

项目总结（整体）